Advancing First-in-Class Condensate Modulators for Previously Inaccessible Targets
- Introducing Dewpoint’s condensate biology platform and its application to the discovery of first-in-class therapeutics across oncology and other disease areas
- Highlighting progress across lead condensate-modulating programs targeting historically inaccessible disease drivers
- Exploring emerging insights into RNA and condensate biology to inform future therapeutic opportunities